Janus Henderson Group PLC Invests $177,000 in Annexon, Inc. (NASDAQ:ANNX)

Janus Henderson Group PLC purchased a new position in Annexon, Inc. (NASDAQ:ANNX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,500 shares of the company’s stock, valued at approximately $177,000.

Other hedge funds have also recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in Annexon during the 4th quarter valued at about $59,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Annexon during the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. raised its stake in shares of Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after acquiring an additional 4,086 shares in the last quarter. Forefront Analytics LLC raised its stake in shares of Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after acquiring an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Annexon in the fourth quarter valued at approximately $98,000.

Annexon Stock Performance

NASDAQ ANNX opened at $2.11 on Monday. Annexon, Inc. has a one year low of $1.29 and a one year high of $7.85. The company has a market capitalization of $231.50 million, a price-to-earnings ratio of -2.01 and a beta of 1.24. The company’s 50-day simple moving average is $1.86 and its two-hundred day simple moving average is $3.44.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07). Equities analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. HC Wainwright reduced their price objective on Annexon from $20.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Needham & Company LLC dropped their price target on Annexon from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.